REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
1 hedge funds and large institutions have $3K invested in REGENERX BIOPHARMACEUTICALS in 2013 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
67% less funds holding
Funds holding: 3 → 1 (-2)
80% less capital invested
Capital invested by funds: $15K → $3K (-$12K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Capital Counsel
New York
|
-$8K |
| 2 |
DDPIC
Deroy & Devereaux Private Investment Counsel
Bloomfield Hills,
Michigan
|
-$3K |
RGN Hedge Fund Activity: Q4 2013 in Review
1 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q4 2013, worth a combined $3K — down 80% from $15K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of RGN and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Capital Counsel, exiting entirely with an estimated $8K sold.
- 1 institutional investor held REGENERX BIOPHARMACEUTICALS (RGN) as of Q4 2013, down from 3 in Q3 2013.
- Funds reported $3K of REGENERX BIOPHARMACEUTICALS stock for Q4 2013, down 80% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q4 2013 and 2 closed out, a net change of -2 holders.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q4 2013 was Capital Counsel, an estimated $8K sold.
Based on aggregated 13F filings for Q4 2013.